 Lumos Pharma Inc NASDAQ: LUMO expects 6-month primary outcome data from Phase 2 OraGrowtH210 Trial of LUM-201 in the 2H of 2023, citing the pace of site initiation and slower than anticipated enrollment due to COVID-19 restrictions. Earlier, the data read-out for the OraGrowtH210 Trial was expected in mid-2022. 